HKSTP
5.11.2021 15:20:09 CET | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) today held its first-ever hybrid Elevator Pitch Competition (EPiC), with over 600 startups from Hong Kong and around the world joining the annual signature event. HKSTP is approaching 20 years of leading innovation in Hong Kong with the return of EPiC 2021 to its iconic home at sky100 at the top of the International Commerce Centre in West Kowloon to re-create a genuine 60-second elevator pitch experience.
In its sixth year, the annual EPiC event in hybrid format for the first time, allowed overseas innovators to go beyond geographical boundaries and join the virtual EPiC event and journey live. This year’s event surpassed all expectations, attracting over 600 entries from 40 countries and cities across five continents. A total of over 160 contestants entered the semi-final round, with nearly 60% from overseas.
This year’s overall EPiC Champion, Winner of Green Tech & Construction Tech Category, as well as the “My Favourite Pitcher” award belong to Hong Kong-based archiREEF. The Greentech startup beat all other finalists with its innovative climate solutions and eco-engineering technology for ocean ecosystems restoration. The company combines expertise in marine biology and the latest technologies in 3D printing techniques and material science to create artificial habitats that are best suited for different marine life anywhere in the world.
The other three tech category winners included: FinTech Winner, Hong Kong-based Wizpresso; Health Technology Winner, Hong Kong-based PointFit Technology, and Smart City Winner, Israel-based Intelligent Traffic Control (ITC). All EPiC entries this year were focused on one of four key themes: FinTech, Green Tech & Construction Tech, Health Technology, and Smart City.
Albert Wong, CEO at HKSTP, said: “The return of our flagship pitching and investment event EPiC 2021 at the iconic sky100 is the ideal platform to lead into our 20th year, while the record participation is a showcase of the city’s growing entrepreneurial strength and world-class I&T potential. The EPiC week of activities provides a unique borderless experience that educates and connects innovators around the world with insights to sharpen entrepreneurial skills and deepen knowledge on the thriving Hong Kong and Greater Bay Area market. EPiC is where we unlock opportunities, where innovation begins and where talent flourishes as pioneers and innovators connect in a genuine haven of global innovation and investment.”
EPiC is a week-long platform generating opportunities not only for the winners but for all participants. Global and local entrepreneurs have interacted with active investors and innovation ecosystem leaders at this year’s EPiC competition. Meanwhile, physical and virtual guests from various industries and territories explored a wealth of GBA and international business partnership, as well as investment opportunities. The competition leads on to the Investment & Business Matching from November 8-12 and finally the Investment Conference on November 12, to complete a week of immersion into HKSTP’s world-class I&T ecosystem.
Since its inception in 2016, HKSTP’s EPiC has drawn a huge number of international participants to grasp a one-minute elevator pitch opportunity to some of the most demanding investors and judges in Hong Kong. The top ten finalists were given another opportunity to face the judges in a three-minute live pitch and two-minute Q&A. The overall champion took away a cash prize of US$100,000, while each of the category winners received a cash prize of US$10,000 and all ten finalists won US$6,000 each.
List of Winners:
Award |
Company |
Market |
Overall Champion and Green Tech & Construction Tech Category Winner |
archiREEF |
Hong Kong |
FinTech Category Winner |
Wizpresso |
Hong Kong |
Health Technology Category Winner |
PointFit Technology |
Hong Kong |
Smart City Category Winner |
Intelligent Traffic Control (ITC) |
Israel |
My Favourite Pitcher |
archiREEF |
Hong Kong |
Other Top 10 Finalists: |
Aortyx |
Spain |
|
Clear Robotics |
Hong Kong |
|
Novai |
UK |
|
Papkot |
France |
|
TicTAP – Simply Connect |
Spain |
|
Vista InnoTech |
Hong Kong |
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for 20 continuous years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong’s leading R&D hub with over 11,000 research professionals and over 1,000 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of the Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realizing a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20211105005610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom